WO1998025902A1 - The preparation of enantiomerically-enriched threo-methylphenidate - Google Patents

The preparation of enantiomerically-enriched threo-methylphenidate Download PDF

Info

Publication number
WO1998025902A1
WO1998025902A1 PCT/GB1997/003418 GB9703418W WO9825902A1 WO 1998025902 A1 WO1998025902 A1 WO 1998025902A1 GB 9703418 W GB9703418 W GB 9703418W WO 9825902 A1 WO9825902 A1 WO 9825902A1
Authority
WO
WIPO (PCT)
Prior art keywords
process according
methylphenidate
acid
crystallisation
threo
Prior art date
Application number
PCT/GB1997/003418
Other languages
French (fr)
Inventor
Susan Faulconbridge
Hooshang Shahriari Zavareh
Graham Robert Evans
Marianne Langston
Original Assignee
Medeva Europe Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9625972.6A external-priority patent/GB9625972D0/en
Priority claimed from GBGB9712298.0A external-priority patent/GB9712298D0/en
Application filed by Medeva Europe Limited filed Critical Medeva Europe Limited
Priority to HU0001604A priority Critical patent/HUP0001604A3/en
Priority to AU78470/98A priority patent/AU7847098A/en
Priority to PL97334136A priority patent/PL334136A1/en
Priority to JP52637898A priority patent/JP2001506621A/en
Priority to CA002272373A priority patent/CA2272373A1/en
Priority to EP97949034A priority patent/EP0948484A1/en
Publication of WO1998025902A1 publication Critical patent/WO1998025902A1/en
Priority to NO992875A priority patent/NO992875L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • This invention relates to processes for the preparation of enantiomerically-enriched f ⁇ re ⁇ -methylphenidate, and in particular to bioresolution, to the separation of the enantiomers of acid addition salt forms of tAre ⁇ -methylphenidate, and to the enhancement of enantiomeric excess (ee) of one enantiomer in a mixture.
  • Methylphenidate is a therapeutic agent that is widely used in the treatment of attention-deficient hyperactivity disorder. It is a controlled substance.
  • Methylphenidate was first prepared as a mixture of the erythro and threo racemates.
  • US-A-2957880 discloses studies upon the two racemic mixtures, which revealed that the therapeutic activity resides in the threo disastereoisomer. It is now considered that it is the d-threo [or (R,R)) enantiomer that has the preferred therapeutic activity. Uses of this enantiomer are disclosed in WO-A-9703671, WO-A-9703672 and WO-A-9703673, the contents of which are incorporated herein by reference.
  • WO-A-9727176 and WO-A-9732851 disclose that the resolution of methylphenidate has also been achieved, more economically, using either O,O '- diaroyltartaric acids or menthoxyacetic acid. These resolutions provide d-threo- methylphenidate in high ee and chemical purity, e.g. containing less than 2% w/w of resolving agent and/or ritalinic acid.
  • racemate and single enantiomers of a salt of a chiral compound such as t ⁇ reo-methylphenidate have different solid-state crystalline forms.
  • Such a salt will have an enantiomeric composition which corresponds to its point of maximum solubility (the eutectic composition), and this is dependent upon the solubility of the racemic salt and the single enantiomer salt.
  • the solubility ratio ⁇ is given by the ratio of the solubility of the racemate salt divided by the solubility of the single enantiomer salt.
  • One aspect of the present invention is based upon the discovery that certain crystalline salts of t/re ⁇ -methylphenidate, wherein the counterion is achiral, allow for the enhancement of enantiomeric excess (ee) by recrystallisation/crystallisation of partially enriched material in a suitable solvent.
  • certain salts of the single enantiomer showed much lower solubility than the corresponding racemate in methanol/TBME (tert-butyl methyl ether).
  • a second aspect of the present invention is based on the discovery that (R,R)- methylphenidate (1) can be conveniently obtained by means of biocatalytic resolution of a racemic compound of formula 2 (of which one enantomer is shown, for convenience), using a range of hydrolase enzymes.
  • crystallisation can be used to give essentially enantiopure t ⁇ re ⁇ -methylphenidate.
  • the starting material should be enantiomerically enriched above the eutectic point of the t ⁇ reo-methylphenidate salt.
  • the eutectic point has been measured to be 25% ee by solubility. That is to say, t//reo-methylphenidate.HCl salt with a composition of enantiomers greater than 25% ee will, by crystallisation, yield enriched material.
  • tAre ⁇ -methylphenidate salts of significantly lower enantiomeric purity in the range 25-95%, preferably 50-95%, and more preferably 70-95%, can be usefully enriched by direct crystallisation.
  • the process of the invention is therefore of considerable utility with a feedstock of t ireo-methylphenidate of moderate enantiomeric purity, for example following classical resolution.
  • Any resolving agent that may be present can be removed, e.g. to a level of 2% w/w or below, e.g. no more than 0.5 or 1% w/w.
  • the novel crystallisation process can be used in combination with the novel biocatalytic resolution.
  • the novel bioresolution encompasses the following embodiments:
  • bioresolution process of the present invention provides a number of benefits, including mild reaction conditions (ambient temperature, low environmental impact), cost savings by avoidance of stoichiometric resolving agents, and easier processing (e.g. simple solvent partitioning in selected cases instead of salt cracking).
  • suitable biocatalysts can readily be identified. It is preferred that the biocatalyst provides a sufficient degree of optical enrichment that the desired product can be used effectively, e.g. at least 20%, preferably at least 40% , and more preferably at least 50% , ee, up to substantially single enantiomer product, e.g. at least 80% or 90% ee.
  • novel crystallisation process is also useful to enhance the ee of material of high ee, e.g. at least 95% ee, if that has been produced in chemically-pure form, using a more efficient resolving agent for this purpose than l, -binaphthyl-2,2'-diyl hydrogen phosphate.
  • a more efficient resolving agent for this purpose than l, -binaphthyl-2,2'-diyl hydrogen phosphate.
  • the solvent that is used in the invention can readily be chosen by those of ordinary skill in the art.
  • the solvent should be sufficiently polar, e.g. an alcohol, optionally together with another solvent such as an ether.
  • An aprotic solvent such as acetonitrile or acetone can also be used.
  • a mixture of methanol and TBME is preferred.
  • the salt used in the invention may have the formula
  • HX is any achiral acid that forms a suitable salt.
  • the suitability of any salt for use in the invention is readily tested in a crystallisation procedure by one of ordinary skill in the art.
  • HX is preferably a hydrohalide, and X is more preferably Br or Cl.
  • racemic £ /-t »reo-methylphenidate.HCl (1.0 g) was suspended in 10 ml of 1 : 1 methanol:TBME (7.4 g) and stirred at 25°C for 16 hours. The solid material was collected by filtration, washing the reaction vessel with 10 ml TMBE. This gave 0.640 g of solid precipitate. The mother liquors were evaporated to dryness to give 0.340 g of a white solid. i//-t ⁇ reo-methylphenidate.HCl therefore has a solubility of 34 mg per ml of 1 : 1 MeOH:TBME at 25°C.
  • the enrichment procedure may also be effected by simply treating a solution of //weo-methylphenidate free base above the eutectic point (>25% ee) with hydrogen chloride in methanol, and isolating the resultant precipitate.
  • Table 2 The results of a series of experiments are given in Table 2.
  • Example 1 95% - d-threo 99.0% (90%) 36.5% (6%) The following Examples illustrate the present invention more specifically.
  • Example 1 95% - d-threo 99.0% (90%) 36.5% (6%)
  • Suitable enzymes for the bioresolution were identified by the following screening protocol: 100 mg of racemic tftre ⁇ -methylphenidate (free base) was dissolved in 100 mM phosphate buffer adjusted to pH 7. Approximately 50 mg (or equivalent ml) of each candidate enzyme was added and the reactions incubated at 30 °C for 24 hours with gentle agitation. For assaying purposes, 40 ⁇ l of the reaction mixture was dispensed into a vial and allowed to evaporate over KOH in a desiccator overnight. The residue was then dissolved in 1 ml IPA/2% diethylamine solution and undissolved material removed by centrifugation.
  • the reaction mixture was then heated at reflux for 5 minutes. After this 30 ml TMBE was added to the reaction mixture which was cooled over one hour to room temperature, and finally at 0°C for 1 hour. The solid material was collected by filtration, washing the reaction vessel with 30 ml TMBE. This gave 13.50 g (77.8%) of solid precipitate, with an enantiomeric excess of 97.8%. The mother liquors were evaporated to dryness to give 3.60 g of a yellow/orange solid (20.7%), with an enantiomeric excess of 32.1%.
  • Example 7 ⁇ i-t 7reo-methylphenidate enriched in the ./-enantiomer (91.3% ee) 11.50 g was taken up in 23 ml of methanol, and stirred at 40-50°C whilst bubbling hydrogen chloride gas through the reaction mixture for 10 minutes. The reaction mixture was then heated at reflux for 5 minutes. After this 23 ml TMBE was added to the reaction mixture which was cooled over one hour to room temperature, and finally at 0°C for 1 hour. The solid material was collected by filtration, washing the reaction vessel with 23 ml TMBE. This gave 10.60 g (79.7%) of solid precipitate, with an enantiomeric excess of 99.2%. The mother liquors were evaporated to dryness to give 2.50 g of a white solid (18.8%), with an enantiomeric excess of 43.6%.
  • the resultant racemic i//-tAre ⁇ -methylphenidate.HBr (0.500 g) was suspended in 5 ml of 1: 1 methanol:TBME (3.80 g) and stirred at 25°C for 16 hours. The solid material was collected by filtration. This gave 0.355 g of solid precipitate. The mother liquors were evaporated to dryness to give 0.140 g of a white solid. /-t/7re ⁇ -methylphenidate.HBr therefore has a solubility of 28 mg per ml of 1 : 1 MeOH:TBME at 25°C.

Abstract

A process for increasing the enantiomeric excess of an enantiomerically-enriched mixture of enantiomers of an acid addition salt of threo-methylphenidate, the acid being achiral, comprises crystallisation from, or partial dissolution in, a solvent; and, if necessary, removing any resolving agent that may be present. This process may be preceded by biocatalytic resolution of racemic threo-methylphenidate or ritalinic acid.

Description

THE PREPARATION OF ENANTIOMERICALLY-ENRICHED 7HREO-METHYLPHENIDATE Field of the Invention
This invention relates to processes for the preparation of enantiomerically-enriched fΛreσ-methylphenidate, and in particular to bioresolution, to the separation of the enantiomers of acid addition salt forms of tAreø-methylphenidate, and to the enhancement of enantiomeric excess (ee) of one enantiomer in a mixture. Background of the Invention
Methylphenidate is a therapeutic agent that is widely used in the treatment of attention-deficient hyperactivity disorder. It is a controlled substance.
Methylphenidate was first prepared as a mixture of the erythro and threo racemates. US-A-2957880 discloses studies upon the two racemic mixtures, which revealed that the therapeutic activity resides in the threo disastereoisomer. It is now considered that it is the d-threo [or (R,R)) enantiomer that has the preferred therapeutic activity. Uses of this enantiomer are disclosed in WO-A-9703671, WO-A-9703672 and WO-A-9703673, the contents of which are incorporated herein by reference.
The resolution of methylphenidate has been achieved using the expensive resolving agent 1,1 '-binaphthyl-2,2'-diyl hydrogen phosphate, a process reported by Patrick et al, The Journal of Pharmacology and Experimental Therapeutics, 241 : 152-158 (1987). Patrick et al also disclose a modest improvement in the enantiopurity of threo- methylphenidate hydrochloride, by crystallisation, from 95-97% to 99% ee. It is now known that the product is contaminated with resolving agent and/or ritalinic acid; see WO- A-9727176.
WO-A-9727176 and WO-A-9732851 disclose that the resolution of methylphenidate has also been achieved, more economically, using either O,O '- diaroyltartaric acids or menthoxyacetic acid. These resolutions provide d-threo- methylphenidate in high ee and chemical purity, e.g. containing less than 2% w/w of resolving agent and/or ritalinic acid.
Generally speaking, the racemate and single enantiomers of a salt of a chiral compound such as tΛreo-methylphenidate have different solid-state crystalline forms.
Consequently, in solution, such a salt will have an enantiomeric composition which corresponds to its point of maximum solubility (the eutectic composition), and this is dependent upon the solubility of the racemic salt and the single enantiomer salt. The solubility ratio α is given by the ratio of the solubility of the racemate salt divided by the solubility of the single enantiomer salt. Summary of the Invention
One aspect of the present invention is based upon the discovery that certain crystalline salts of t/reø-methylphenidate, wherein the counterion is achiral, allow for the enhancement of enantiomeric excess (ee) by recrystallisation/crystallisation of partially enriched material in a suitable solvent. In particular, it has surprisingly been found that, in the case of tΛreo-methylphenidate, certain salts of the single enantiomer showed much lower solubility than the corresponding racemate in methanol/TBME (tert-butyl methyl ether).
A second aspect of the present invention is based on the discovery that (R,R)- methylphenidate (1) can be conveniently obtained by means of biocatalytic resolution of a racemic compound of formula 2 (of which one enantomer is shown, for convenience), using a range of hydrolase enzymes.
Figure imgf000004_0001
Description of the Invention According to the first aspect of this invention, and by appropriate use of partially enantiomerically-enriched salt, crystallisation can be used to give essentially enantiopure tΛreσ-methylphenidate. The starting material should be enantiomerically enriched above the eutectic point of the tΛreo-methylphenidate salt. In the case of tΛreo-methylphenidate hydrochloride salt, the eutectic point has been measured to be 25% ee by solubility. That is to say, t//reo-methylphenidate.HCl salt with a composition of enantiomers greater than 25% ee will, by crystallisation, yield enriched material. Thus, by contrast with the crystallisation reported by Patrick et al, supra, tAreø-methylphenidate salts of significantly lower enantiomeric purity, in the range 25-95%, preferably 50-95%, and more preferably 70-95%, can be usefully enriched by direct crystallisation. The process of the invention is therefore of considerable utility with a feedstock of t ireo-methylphenidate of moderate enantiomeric purity, for example following classical resolution. Any resolving agent that may be present can be removed, e.g. to a level of 2% w/w or below, e.g. no more than 0.5 or 1% w/w. Preferably, there is no chemical resolving agent, as in bioresolution or asymmetric synthesis. In the latter two cases at least, the feedstock is uncontaminated by resolving agent. For example, the novel crystallisation process can be used in combination with the novel biocatalytic resolution. By way of example, the novel bioresolution encompasses the following embodiments:
(i) where R = Me, enantioselective hydrolysis of unwanted (S,S)- methylphenidate (l-threό) affords (5,5)-ritalinic acid, which is easily separated from unreacted (7?,/?)-methylphenidate by extraction into dilute aqueous alkali. (ii) where R = Me (or another lower alkyl group), enantioselective hydrolysis of (Λ, ?)-methylphenidate (d-threo) is followed by isolation of (/?,/?)-ritalinic acid and chemical esterification. To maximise atom utilisation, recycling of the unreacted (S,S)-methylphenidate (l-threό) may be carried out according to the procedure described in WO-A-9728124. (iii) where R = H, enantioselective esterification of (/?,/?)-ritalinic acid affords (/?,/?)-methylphenidate directly.
(iv) where R = H, enantioselective esterification of (5,5)-ritalinic acid, is followed by separation from the (/?,/?)-antipode, and chemical esterification of the latter. Compared with classical resolution, the bioresolution process of the present invention provides a number of benefits, including mild reaction conditions (ambient temperature, low environmental impact), cost savings by avoidance of stoichiometric resolving agents, and easier processing (e.g. simple solvent partitioning in selected cases instead of salt cracking). As will be apparent from Example 1, suitable biocatalysts can readily be identified. It is preferred that the biocatalyst provides a sufficient degree of optical enrichment that the desired product can be used effectively, e.g. at least 20%, preferably at least 40% , and more preferably at least 50% , ee, up to substantially single enantiomer product, e.g. at least 80% or 90% ee.
The novel crystallisation process is also useful to enhance the ee of material of high ee, e.g. at least 95% ee, if that has been produced in chemically-pure form, using a more efficient resolving agent for this purpose than l, -binaphthyl-2,2'-diyl hydrogen phosphate. Such processes are described in WO-A-9727176 and WO-A-9732851.
The solvent that is used in the invention can readily be chosen by those of ordinary skill in the art. For example, the solvent should be sufficiently polar, e.g. an alcohol, optionally together with another solvent such as an ether. An aprotic solvent such as acetonitrile or acetone can also be used. A mixture of methanol and TBME is preferred.
The salt used in the invention may have the formula
Figure imgf000006_0001
wherein HX is any achiral acid that forms a suitable salt. The suitability of any salt for use in the invention is readily tested in a crystallisation procedure by one of ordinary skill in the art. HX is preferably a hydrohalide, and X is more preferably Br or Cl.
For the purposes of comparison, racemic £ /-t »reo-methylphenidate.HCl (1.0 g) was suspended in 10 ml of 1 : 1 methanol:TBME (7.4 g) and stirred at 25°C for 16 hours. The solid material was collected by filtration, washing the reaction vessel with 10 ml TMBE. This gave 0.640 g of solid precipitate. The mother liquors were evaporated to dryness to give 0.340 g of a white solid. i//-t ιreo-methylphenidate.HCl therefore has a solubility of 34 mg per ml of 1 : 1 MeOH:TBME at 25°C.
This experiment was repeated using 20% ee, 25% ee and single enantiomer d- t weσ-methylphenidate.HCI. These and other solubility results, obtained using essentially the same procedure, are reported in Table 1. In the Tables, MPH = threo- methylphenidate, PPT = precipitate, and MLS = mother liquor. Table 1 shows solubility measurements for t ?reo-methylphenidate hydrochloride of different enantiomeric composition (racemate, or enriched in the ./enantiomer), and also demonstrates one embodiment of the present invention, namely the ee enhancement achieved by dissolution of the materials in a 1 : 1 mixture of methanol:TBME at 25°C, and separation of insoluble material. The point of maximum solubility is at 25% ee, which defines the eutectic composition and the solubility ratio α= 34.0/17.0 = 2.0. Enhancement of ee is slight when the initial ee is 30%, increasing to 31.9%, but a progressive enhancement is observed when the initial ee is higher. Table 1 ee MPH.HC1 ee PPT ee MLS Solubility (mg/per ml)
0% - - 34.0
20% 15.9% 25.0% 36.0
25% 19.9% 24.7% 40.0
30% 31.9% 22.6% 33.0
50% 54.4% 24.3% 27.7
60% 70.7% 25.1% 26.5
73% 93.0% 46.0% 25.5
99% _ _ 17.0
In another embodiment of the present invention, the enrichment procedure may also be effected by simply treating a solution of //weo-methylphenidate free base above the eutectic point (>25% ee) with hydrogen chloride in methanol, and isolating the resultant precipitate. The results of a series of experiments are given in Table 2.
Table 2 ee MPH ee PPT (% yield) ee MLS (% yield)
82% - l-threo 97.0% (65%) 36.9% (35%)
87% - l-threo 98.0% (69%) 35.7% (23%)
88% - l-threo 97.8% (78%) 32.1% (21%) 9\% - d-threo 99.2% (80%) 43.6% (19%)
94% - d-threo 99.7% (86%) 72.3% (8%)
95% - d-threo 99.0% (90%) 36.5% (6%) The following Examples illustrate the present invention more specifically. Example 1
Suitable enzymes for the bioresolution were identified by the following screening protocol: 100 mg of racemic tftreø-methylphenidate (free base) was dissolved in 100 mM phosphate buffer adjusted to pH 7. Approximately 50 mg (or equivalent ml) of each candidate enzyme was added and the reactions incubated at 30 °C for 24 hours with gentle agitation. For assaying purposes, 40 μl of the reaction mixture was dispensed into a vial and allowed to evaporate over KOH in a desiccator overnight. The residue was then dissolved in 1 ml IPA/2% diethylamine solution and undissolved material removed by centrifugation. The enantiomeric composition of the unreacted threo- methylphenidate remaining in solution was analysed by hplc method on the Chirapak AD column using 90: 10:0.2 heptane/IPA/diethylamine at 0.5 ml/min and λ=227 nm. Any ritalinic acid also present in the solution was found not to interfere with the detection of the enantiomeric methyl esters.
A representative result was obtained using α-chymotrypsin (Sigma). Its use gave a ratio of enantiomers of unreacted substrate (SS.RR) of 79.5:20.5. Example 2
£/-tΛreø-methylphenidate.HCl enriched in the -enantiomer (73% ee) (0.950 g) was suspended in 10 ml of 1 : 1 methanol:TBME (7.7 g) and stirred at 25°C for 16 hours. The solid material was collected by filtration, washing the reaction vessel with 10 ml TMBE. This gave 0.725 g of solid precipitate, with an enantiomeric excess of 93.0%. The mother liquors were evaporated to dryness to give 0.255 g of a white solid, with an enantiomeric excess of 46.0%. -/-t/weσ-methylphenidate.HCl (73% ee) therefore has a solubility of 25.5 mg per ml of 1 : 1 MeOH:TBME at 25°C. Example 3
-/-tAreo-methylphenidate.HCl enriched in the c -enantiomer (50% ee) (1.00 g) was suspended in 10 ml of 1 : 1 methanol:TBME (7.9 g) and stirred at 25°C for 16 hours. The solid material was collected by filtration, washing the reaction vessel with 10 ml TMBE. This gave 0.710 g of solid precipitate, with an enantiomeric excess of 54.4%. The mother liquors were evaporated to dryness to give 0.277 g of a white solid, with an enantiomeric excess of 24.3%. c/-t /reo-methylphenidate.HCl (50.0% ee) therefore has a solubility of 27.7 mg per ml of 1 : 1 MeOH:TBME at 25°C. Example 4
./-t/jreo-methylphenidate.HCl enriched in the ./-enantiomer (60% ee) (1.00 g) was suspended in 10 ml of 1 : 1 methanol:TBME (7.7 g) and stirred at 25°C for 16 hours. The solid material was collected by filtration, washing the reaction vessel with 10 ml TMBE. This gave 0.710 g of solid precipitate, with an enantiomeric excess of 70.7%. The mother liquors were evaporated to dryness to give 0.265 g of a white solid, with an enantiomeric excess of 25.1%../-tΛreø-methylphenidate.HCl (60% ee) therefore has a solubility of 26.5 mg per ml of 1 : 1 MeOH:TBME at 25°C. Example 5 -tΛreo-methylphenidate.HCl enriched in the ./-enantiomer (30% ee) (1.00 g) was suspended in 10 ml of 1 : 1 methanol:TBME(7.7 g) and stirred at 25°C for 16 hours. The solid material was collected by filtration, washing the reaction vessel with 10 ml TMBE. This gave 0.655 g of solid precipitate, with an enantiomeric excess of 31.9%. The mother liquors were evaporated to dryness to give 0.330 g of a white solid, with an enantiomeric excess of 22.6%. £/-t/;reø-methylphenidate.HCl (30% ee) therefore has a solubility of 33.0 mg per ml of 1 : 1 MeOH:TBME at 25°C. Example 6 /-t weø-methylphenidate enriched in the /-enantiomer (88.3% ee) 15.0 g was taken up in 30 ml of methanol, and stirred at 40-50°C whilst bubbling hydrogen chloride gas through the reaction mixture for 10 minutes. The reaction mixture was then heated at reflux for 5 minutes. After this 30 ml TMBE was added to the reaction mixture which was cooled over one hour to room temperature, and finally at 0°C for 1 hour. The solid material was collected by filtration, washing the reaction vessel with 30 ml TMBE. This gave 13.50 g (77.8%) of solid precipitate, with an enantiomeric excess of 97.8%. The mother liquors were evaporated to dryness to give 3.60 g of a yellow/orange solid (20.7%), with an enantiomeric excess of 32.1%. Example 7 <i-t 7reo-methylphenidate enriched in the ./-enantiomer (91.3% ee) 11.50 g was taken up in 23 ml of methanol, and stirred at 40-50°C whilst bubbling hydrogen chloride gas through the reaction mixture for 10 minutes. The reaction mixture was then heated at reflux for 5 minutes. After this 23 ml TMBE was added to the reaction mixture which was cooled over one hour to room temperature, and finally at 0°C for 1 hour. The solid material was collected by filtration, washing the reaction vessel with 23 ml TMBE. This gave 10.60 g (79.7%) of solid precipitate, with an enantiomeric excess of 99.2%. The mother liquors were evaporated to dryness to give 2.50 g of a white solid (18.8%), with an enantiomeric excess of 43.6%.
In order to demonstrate the broader applicability of the invention, the corresponding hydrobromide salt was prepared. Firstly, dZ-tΛreø-methylphenidate (0.86 g; 3.71 mmol) and ammonium bromide (0.436 g; 4.45 mmol) were taken up in 10 ml methanol and stirred at 25°C for 10 minutes. The solvent was removed under vacuum, this process being repeated a further two times. The resulting white crystalline material was taken up in 25 ml dichloromethane, and filtered through Celite. This gave 0.97 g of a white solid (83.3%). MP = 205.6°C. IR (KBr) υ^ = 1730 cm"1.
The resultant racemic i//-tAreø-methylphenidate.HBr (0.500 g) was suspended in 5 ml of 1: 1 methanol:TBME (3.80 g) and stirred at 25°C for 16 hours. The solid material was collected by filtration. This gave 0.355 g of solid precipitate. The mother liquors were evaporated to dryness to give 0.140 g of a white solid. /-t/7reø-methylphenidate.HBr therefore has a solubility of 28 mg per ml of 1 : 1 MeOH:TBME at 25°C.
Secondly, c/-t ?reø-methylphenidate (0.86 g; 3.71 mmol) and ammonium bromide (0.436 g; 4.45 mmol) were taken up in 10 ml of methanol and stirred at 25°C for 10 minutes. The solvent was removed under vacuum, this process being repeated a further two times. The resulting white crystalline material was taken up in 25 ml dichloromethane, and filtered through Celite. This gave 0.75 g of a white solid (64.4%). MP = 222.6°C. IR (KBr) υnux = 1730 cm-1. The resultant single enantiomer ./-t/?reσ-methylphenidate.HBr (1.0 g) was suspended in 5 ml of 1 : 1 methanol:TBME (4.00 g) and stirred at 25°C for 16 hours. The solid material was collected by filtration. This gave 0.430 g of solid precipitate. The mother liquors were evaporated to dryness to give 0.070 g of a white solid, d-threo- methylphenidate.HBr therefore has a solubility of 14.0 mg per ml of 1 : 1 MeOH:TBME at 25°C.

Claims

1. A process for increasing the enantiomeric excess of an enantiomerically- enriched mixture of enantiomers of an acid addition salt of /Λreø-methylphenidate, wherein said acid is achiral, which comprises crystallisation from, or partial dissolution in, a solvent; and, if necessary, removing any resolving agent that may be present.
2. A process according to claim 1, wherein crystallisation follows dissolution of the pre-formed acid addition salt in a solvent.
3. A process according to claim 1 , wherein crystallisation follows addition of the acid to a solution of /Λreø-methylphenidate free base.
4. A process according to any preceding claim, wherein, prior to crystallisation of the acid addition salt, the initial ee is at least 25% ee.
5. A process according to claim 4, wherein the initial ee is 25 to 95%.
6. A process according to claim 4, wherein the initial ee is 50 to 95%.
7. A process according to claim 4, wherein the initial ee is 70 to 95%.
8. A process according to any preceding claim, wherein the mixture of enantiomers contains less than 2% w/w resolving agent.
9. A process according to any preceding claim, wherein the acid is a hydrohalide.
10. A process according to claim 9, wherein the acid is HC1.
11. A process according to claim 9, wherein the acid is HBr.
12. A process according to any preceding claim, for the preparation of d-threo methylphenidate hydrochloride of enantiomeric purity in excess of 98% ee.
13. A process according to any preceding claim, which follows classical resolution and, optionally, removal of resolving agent.
14. A process according to any of claims 1 to 12, which follows asymmetric synthesis.
15. A process according to any of claims 1 to 12, which follows bioresolution.
16. A process for preparing enantiomerically-enriched d, tλreσ-methylphenidate, which comprises biocatalytic resolution of a racemic compound of the formula
Figure imgf000011_0001
wherein the relative stereochemistry is threo, and R is H or methyl.
17. A process according to claim 16, wherein racemic tAreø-methylphenidate is subjected to hydrolysis in the presence of an enzyme that displays enantioselectivity.
18. A process according to claim 16, wherein racemic ritalinic acid is subjected to esterification in the presence of an enzyme that displays enantioselectivity.
19. A process according to claim 17 or claim 18, which additionally comprises conventional chemical esterification of (R,R)-ritalinic acid.
20. A process according to any of claims 17 to 19, wherein the enzyme is α-chymotrypsin (bovine pancreas).
21. A process according to any of claims 16 to 20, wherein the enzyme is in immobilised form.
22. A process according to claim 15, wherein the bioresolution is a process according to any of claims 16 to 21.
PCT/GB1997/003418 1996-12-13 1997-12-11 The preparation of enantiomerically-enriched threo-methylphenidate WO1998025902A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
HU0001604A HUP0001604A3 (en) 1996-12-13 1997-12-11 The preparation of an enantiomerically-enriched threo-methylphenidate
AU78470/98A AU7847098A (en) 1996-12-13 1997-12-11 The preparation of enantiomerically-enriched threo- methylphenidate
PL97334136A PL334136A1 (en) 1996-12-13 1997-12-11 Method of obtaining enantiomerically enriched methyl threophenidate
JP52637898A JP2001506621A (en) 1996-12-13 1997-12-11 Preparation of enantiomerically enriched threo-methylphenidate
CA002272373A CA2272373A1 (en) 1996-12-13 1997-12-11 The preparation of enantiomerically-enriched threo-methylphenidate
EP97949034A EP0948484A1 (en) 1996-12-13 1997-12-11 The preparation of enantiomerically-enriched threo-methylphenidate
NO992875A NO992875L (en) 1996-12-13 1999-06-11 Preparation of enantiomerically enriched threo-methylphenidate

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9625972.6A GB9625972D0 (en) 1996-12-13 1996-12-13 Bioresolution
GB9625972.6 1996-12-13
GB9712298.0 1997-06-12
GBGB9712298.0A GB9712298D0 (en) 1997-06-12 1997-06-12 Crystallisation

Publications (1)

Publication Number Publication Date
WO1998025902A1 true WO1998025902A1 (en) 1998-06-18

Family

ID=26310627

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/003418 WO1998025902A1 (en) 1996-12-13 1997-12-11 The preparation of enantiomerically-enriched threo-methylphenidate

Country Status (9)

Country Link
EP (1) EP0948484A1 (en)
JP (1) JP2001506621A (en)
AU (1) AU7847098A (en)
CA (1) CA2272373A1 (en)
CZ (1) CZ206299A3 (en)
HU (1) HUP0001604A3 (en)
NO (1) NO992875L (en)
PL (1) PL334136A1 (en)
WO (1) WO1998025902A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025502A (en) * 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate
US6100401A (en) * 1998-04-20 2000-08-08 Novartris Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
US6127385A (en) * 1999-03-04 2000-10-03 Pharmaquest Limited Method of treating depression using l-threo-methylphenidate
US6162919A (en) * 1998-12-03 2000-12-19 Novartis Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
EP1163907A1 (en) * 2000-06-17 2001-12-19 Pharmaquest Limited Use of l-threo-methylphenidate for the treatment of depression
US6395752B1 (en) * 1999-03-04 2002-05-28 Pharmaquest Limited Method of treating depression using 1-threo-methylphenidate
EP1292305A1 (en) * 2000-04-12 2003-03-19 THE McLEAN HOSPITAL CORPORATION METHOD OF DOPAMINE INHIBITION USING i L-THREO /i -METHYLPHENIDATE
WO2004080959A2 (en) * 2003-03-07 2004-09-23 Isp Investments Inc. Process for the preparation of dexmethylphenidate hydrochloride
US7115631B2 (en) 1995-12-04 2006-10-03 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US7897777B2 (en) 2007-01-05 2011-03-01 Archimica, Inc. Process of enantiomeric resolution of D,L-(±)-threo-methylphenidate
WO2012080834A1 (en) 2010-12-17 2012-06-21 Rhodes Technologies Low-temperature synthesis of methylphenidate hydrochloride
US8552030B2 (en) 2009-05-07 2013-10-08 Malladi Drugs & Pharmaceuticals Ltd. Process for the preparation of d-threo-ritalinic acid hydrochloride by resolution of dl-threo-ritalinic acid using chiral carboxylic acid
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9028868B2 (en) 2011-03-23 2015-05-12 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9233924B2 (en) 2014-03-11 2016-01-12 Ampac Fine Chemicals Llc Methods for preparing D-threo methylphenidate using diazomethane, and compositions thereof
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10081597B2 (en) 2014-06-27 2018-09-25 Embio Limited Process for preparation of dexmethylphenidate hydrochloride
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241392B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02190195A (en) * 1989-01-19 1990-07-26 Rikagaku Kenkyusho Production of optically active propionic acid ester compound
EP0387068A1 (en) * 1989-03-08 1990-09-12 Wisconsin Alumni Research Foundation Improving the enantioselectivity of biocatalytic resolution of racemic compounds
EP0623678A2 (en) * 1993-04-22 1994-11-09 Shionogi & Co., Ltd. Norbornane type ester hydrolase
WO1995003421A1 (en) * 1993-07-19 1995-02-02 Dsm N.V. Process for the enzymatic preparation of optically active n-substituted-3-pyrrolidinol
EP0687736A1 (en) * 1994-06-15 1995-12-20 Basf Aktiengesellschaft Method for the preparation of enantiomerically pure lactams

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02190195A (en) * 1989-01-19 1990-07-26 Rikagaku Kenkyusho Production of optically active propionic acid ester compound
EP0387068A1 (en) * 1989-03-08 1990-09-12 Wisconsin Alumni Research Foundation Improving the enantioselectivity of biocatalytic resolution of racemic compounds
EP0623678A2 (en) * 1993-04-22 1994-11-09 Shionogi & Co., Ltd. Norbornane type ester hydrolase
WO1995003421A1 (en) * 1993-07-19 1995-02-02 Dsm N.V. Process for the enzymatic preparation of optically active n-substituted-3-pyrrolidinol
EP0687736A1 (en) * 1994-06-15 1995-12-20 Basf Aktiengesellschaft Method for the preparation of enantiomerically pure lactams

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 9036, Derwent World Patents Index; Class B05, AN 90-271113, XP002059042 *
PATRICK K S ET AL: "PHARMACOLOGY OF THE ENANTIOMERS OF THREO-METHYLPHENIDATE", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 241, no. 1, April 1987 (1987-04-01), pages 152 - 158, XP000602302 *
SHIEH W -C ET AL: "ASYMMETRIC TRANSFORMATION OF EITHER ENANTIOMER OF NARWEDINE VIA TOTAL SPONTANEOUS RESOLUTION PROCESS A CONCISE SOLUTION TO THE SYNTHESIS OF (-)-GALANTHAMINE", JOURNAL OF ORGANIC CHEMISTRY, vol. 59, no. 18, 9 September 1994 (1994-09-09), pages 5463 - 5465, XP000562837 *

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115631B2 (en) 1995-12-04 2006-10-03 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US6100401A (en) * 1998-04-20 2000-08-08 Novartris Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
US6162919A (en) * 1998-12-03 2000-12-19 Novartis Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
US6127385A (en) * 1999-03-04 2000-10-03 Pharmaquest Limited Method of treating depression using l-threo-methylphenidate
US6395752B1 (en) * 1999-03-04 2002-05-28 Pharmaquest Limited Method of treating depression using 1-threo-methylphenidate
US6025502A (en) * 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate
EP1292305A1 (en) * 2000-04-12 2003-03-19 THE McLEAN HOSPITAL CORPORATION METHOD OF DOPAMINE INHIBITION USING i L-THREO /i -METHYLPHENIDATE
EP1292305A4 (en) * 2000-04-12 2004-04-07 Mclean Hospital Corp METHOD OF DOPAMINE INHIBITION USING i L-THREO /i -METHYLPHENIDATE
EP1163907A1 (en) * 2000-06-17 2001-12-19 Pharmaquest Limited Use of l-threo-methylphenidate for the treatment of depression
WO2004080959A2 (en) * 2003-03-07 2004-09-23 Isp Investments Inc. Process for the preparation of dexmethylphenidate hydrochloride
WO2004080959A3 (en) * 2003-03-07 2004-11-25 Isp Investments Inc Process for the preparation of dexmethylphenidate hydrochloride
US7897777B2 (en) 2007-01-05 2011-03-01 Archimica, Inc. Process of enantiomeric resolution of D,L-(±)-threo-methylphenidate
US8552030B2 (en) 2009-05-07 2013-10-08 Malladi Drugs & Pharmaceuticals Ltd. Process for the preparation of d-threo-ritalinic acid hydrochloride by resolution of dl-threo-ritalinic acid using chiral carboxylic acid
EP2937336A1 (en) 2010-12-17 2015-10-28 Rhodes Technologies Low-temperature synthesis of methylphenidate hydrochloride
WO2012080834A1 (en) 2010-12-17 2012-06-21 Rhodes Technologies Low-temperature synthesis of methylphenidate hydrochloride
US9475770B2 (en) 2010-12-17 2016-10-25 Rhodes Technologies Low-temperature synthesis of methylphenidate hydrochloride
US9511032B2 (en) 2011-03-23 2016-12-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9023389B1 (en) 2011-03-23 2015-05-05 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603808B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Method of treatment of attention deficit hyperactivity disorder
US11911518B2 (en) 2011-03-23 2024-02-27 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9889095B2 (en) 2011-03-23 2018-02-13 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9034902B2 (en) 2011-03-23 2015-05-19 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9028868B2 (en) 2011-03-23 2015-05-12 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US9289394B2 (en) 2011-03-23 2016-03-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241392B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10179108B2 (en) 2011-03-23 2019-01-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10182995B2 (en) 2011-03-23 2019-01-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10617651B2 (en) 2011-03-23 2020-04-14 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10881618B2 (en) 2011-03-23 2021-01-05 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9573896B2 (en) 2014-03-11 2017-02-21 Ampac Fine Chemicals Llc Methods for preparing d-threo-methylphenidate using diazomethane, and compositions thereof
US9233924B2 (en) 2014-03-11 2016-01-12 Ampac Fine Chemicals Llc Methods for preparing D-threo methylphenidate using diazomethane, and compositions thereof
US10081597B2 (en) 2014-06-27 2018-09-25 Embio Limited Process for preparation of dexmethylphenidate hydrochloride

Also Published As

Publication number Publication date
AU7847098A (en) 1998-07-03
NO992875D0 (en) 1999-06-11
NO992875L (en) 1999-06-14
HUP0001604A3 (en) 2003-03-28
EP0948484A1 (en) 1999-10-13
CZ206299A3 (en) 1999-09-15
CA2272373A1 (en) 1998-06-18
HUP0001604A2 (en) 2000-10-28
JP2001506621A (en) 2001-05-22
PL334136A1 (en) 2000-02-14

Similar Documents

Publication Publication Date Title
WO1998025902A1 (en) The preparation of enantiomerically-enriched threo-methylphenidate
US5258517A (en) Method of preparing optically pure precursors of paroxetine
US20090087888A1 (en) Production of monatin stereoisomers
EP0206436A2 (en) Enzymatic production of optical isomers of 2-halopropionic acids
US7126003B2 (en) Method for producing 2-azetidinone derivative
RU2108393C1 (en) Method for stereospecific hydrolysis of piperidinedione derivatives
EP0440723B1 (en) Process for preparing optically active glycidate esters
WO2014030106A2 (en) Process for preparation of optically active (2r,3s)-3-(4- methoxyphenyl)glycidic acid methyl ester and cis lactam and uses thereof
EP1532146B1 (en) A method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives
EP0602740B1 (en) Process for the enzymatic preparation of optically active transglycidic acid esters
US6069270A (en) Optical resolution method of (±)-3,4-dihydroxybutanoic acid
KR100378741B1 (en) Method for preparing R- or S-form α-substituted heterocyclic carboxyl acid and counter enantiomeric form of α-substituted heterocyclic carboxyl acid ester thereto using enzyme
US6153414A (en) Method for racemic biochemical resolution of CIS-and trans-pyprolopiperidine
JP4843812B2 (en) Method for optical resolution of racemic α-substituted heterocyclic carboxylic acids using enzymes
KR100368735B1 (en) Method for preparing R- or S-form α-substituted heterocyclic carboxyl acid using enzyme
EP1280775A1 (en) TOSYLATE SALTS OF 4-(p-FLUOROPHENYL)-PIPERIDINE-3-CARBINOLS
EP0239122A2 (en) Process for the enzymatic resolution of racemic 2-amino-1-alkanols
KR100617952B1 (en) Method for manufacturing the pirdo-benz-oxizine for optical a ativity
WO2008125914A2 (en) Process of enantiomeric resolution of d,l-( + )-threo-methylphenidate
EP1355882B1 (en) Chiral scaffolds and their preparation
JP2009522230A (en) From racemic 4- (1-aminoethyl) benzoic acid methyl ester to (R)-and (S) -4- (1-ammoniumethyl) by enantioselective acylation using a lipase catalyst followed by precipitation with sulfuric acid. Method for preparing benzoic acid methyl ester sulfate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997949034

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2272373

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PV1999-2062

Country of ref document: CZ

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 526378

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: PV1999-2062

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1997949034

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1997949034

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1999-2062

Country of ref document: CZ